Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Goodwill Impairment

Restructuring costs

Intangible assets and other long-lived assets impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bionano Genomics

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bionano Genomics reports robust Q1 performance and strategic growth plans

Bionano Genomics demonstrated strong revenue growth and operational progress in Q1 2024.
While facing short-term revenue challenges, the company's strategic initiatives and product advancements position it for long-term success.
Efforts to reduce expenses and expand the customer base underscore Bionano's commitment to sustainable growth.

Bionano Genomics reports Q2 revenue decline, focuses on growth strategies

Bionano Genomics faced revenue decline in Q2 2024, attributed to discontinued services and challenges in China.
Despite operational streamlining efforts, the company aims to drive growth through product advancements and partnerships.
Lowered revenue guidance underscores the need for strategic adjustments to navigate market challenges and optimize performance.

Bionano Genomics reports Q3 revenue decline but shows cost efficiency

Bionano Genomics showcased operational improvements with cost reductions and growth in key metrics despite a revenue decline.
The company's focus on expense reduction, revenue growth, and profitability sets a strategic direction for future success.
Challenges persist in revenue generation and cost management, but opportunities in technology adoption and market expansion are evident.
Overall, Bionano Genomics aims to balance financial stability with growth initiatives to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bionano Genomics, Inc. (BNGO) CEO Robert Holmlin Presents at Oppenheimer MedTech, Tools & Diagnostics Summit Conference (Transcript)

SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the Oppenheimer MedTech, Tools & Diagnostics Summit being held on May 26, 2021.

Bionano Genomics to Present at the 2021 Oppenheimer MedTech, Tools & Diagnostic Summit

Bionano Genomics recently reported healthy Saphyr Systems sales in the first quarter. As a result, BNGO stock gained over 20%.

Bionano Genomics Moves Into Speculative Buy Territory

Express

GT Biopharma Inc

Mustang Bio

McEwen Mining

Penny stocks remain volatile but these analysts have a bright outlook on these The post 5 Penny Stocks To Watch Right Now That Analysts Are Bullish On appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch Right Now That Analysts Are Bullish On

Marathon Digital Holdings

Novavax

Plug Power

Riot Blockchain

Are these popular momentum stocks too cheap to ignore or blatant value traps?

5 Risky Stocks With 138% to 216% Upside, According to Wall Street

Bionano Genomics can't kick the cash-raising bug. BNGO stock could fall to $1.85, its potential cash per share if it continues to raise cash.

Bionano Genomics Just Can't Kick the Cash-Raising Bug With All Its Dilution

The company reported better-than-expected Q1 revenue growth.

Why Bionano Genomics Stock Is Skyrocketing Today

CorMedix

Eloxx Pharmaceuticals Inc

Bionano Genomics, Inc. (NASDAQ: BNGO), CorMedix Inc. (NASDAQ: CRMD) and Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) are among the health care movers Friday. Bionano Moves On Q1 Results: Bionano reported first-quarter revenues of $3.2 million, up 179% year-over-year.

Why Bionano Genomics, CorMedix and Eloxx Are Moving Friday

Aikido Pharma Inc.

Actinium Pharmaceuticals

Atossa Genetics

CTI BioPharma

Immutep Ltd

Onconova Therapeutics

These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on InvestorPlace.

7 Reddit Penny Stocks Promising to Cure Cancer

BIOLASE

SNDL Inc.

These penny stocks gapped up big this morning; are they worth watching? The post 3 Penny Stocks That Gapped Up Big in Early Morning Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks That Gapped Up Big in Early Morning Trading

The stock price of Bionano Genomics, Inc. (NASDAQ: BNGO) increased by over 10% pre-market. This is why it happened.

Bionano Genomics (BNGO) Stock: Over 10% Increase Pre-Market Explanation

The company delivered a pleasant surprise.

Here's What Investors Liked About Bionano Genomics' Q1 Results

Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin on Q1 2021 Results - Earnings Call Transcript

BioNano Genomics Inc (NASDAQ:BNGO) shares traded higher by 6.9% to $4.41 after the company reported better-than-expected first-quarter sales results. Bionano Genomics reported quarterly sales of $3.2 million, which beat the analyst consensus estimate of $2.9 million.

Why BioNano Genomics Traded Higher Today

Bionano Genomics Inc. BNGO shares rallied in the extended session Thursday after the genome analysis company's quarterly revenue came in better than Wall Street expected. Bionano shares surged 10% after hours, following a 7% decline in the regular session to close at $4.41.

Bionano Genomics stock jumps as revenue beats Street

SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today reported financial results and business achievements for the first quarter ended March 31, 2021 and highlighted recent corporate updates.

Bionano Genomics Reports First Quarter 2021 Financial Results and Highlights Recent Business Progress

BioNano Genomics (NASDAQ:BNGO) is testing an important support at the $5 level. If this support breaks, shares could make a rapid and large move lower.

Is Reddit Favorite BioNano Genomics About To Nosedive?

Don't mistake Bionano for just any Reddit stock. With its Q1 earnings looming, BNGO stock is attractively priced near its 2021 low.

Is Bionano Genomics a Buy Ahead of Earnings?

Investors need to pay close attention to Bionano Genomics (BNGO) stock based on the movements in the options market lately.

Implied Volatility Surging for Bionano Genomics (BNGO) Stock Options

AMC Entertainment

Citius Pharmaceuticals

Nokia

Tenet Healthcare

We're taking another dive into the world of penny stocks on Tuesday with a look at Reddit's most-talked-about for the day. The post 5 Reddit Penny Stocks Seeing the Most Chatter Tuesday appeared first on InvestorPlace.

5 Reddit Penny Stocks Seeing the Most Chatter Tuesday

Bionano Genomics (BNGO) is expected to provide updates on its earnings and revenues when it reports first-quarter 2021 result.

Bionano (BNGO) to Report Q1 Earnings: What's in the Cards?

Bionano Genomics has lost a lot of supporters in recent months and some never came to the rescue, but a lifeline has been thrown to BNGO stock. The post Don't Look Now, but Bionano Genomics May Be a Buy appeared first on InvestorPlace.

Don't Look Now, but Bionano Genomics May Be a Buy

The science underlining BNGO stock is incredibly compelling. But that's not what the market actually cares about right now.

Don't Confuse Bionano Genomics As an Investment Right Now

It's hard to reconcile the sell-off in BNGO stock with Bionano's progress in advancing the Saphyr system - but this presents an opportunity. The post Bionano Genomics Has Disappointed, but Its NHS Deal May Turn Things Around appeared first on InvestorPlace.

Bionano Genomics Has Disappointed, but Its NHS Deal May Turn Things Around

Bionano Genomics, Inc. (BNGO) closed the most recent trading day at $6.97, moving -1.13% from the previous trading session.

News for Bionano Genomics Stock (BNGO)